This review delves into the current clinical status, efficacy, safety profiles, and regulatory approvals of third-generation EGFR TKIs, including Osimertinib, Lazertinib, Furmonertinib, Aumolertinib, Rezivertinib, Befotertinib, Sunvozertinib...Notable fourth-generation candidates such as TQB3804, BPI-361175, BDTX-1535, WJ13404, QLH11811, H002, HS-10375, BBT-207, JIN-A02, and HS-10504 are highlighted for their potential to overcome the C797S mutation...By evaluating the therapeutic potential and limitations of these EGFR TKIs, this review aims to guide future research in the management of EGFR-mutant NSCLC. This acts as guiding beacon for the strategic design and development of third and fourth generation EGFR-TK inhibitors to overcome the drug resistance hurdles in the development of EGFR-TK inhibitors.

8 months ago

Review • Journal

EGFR (Epidermal growth factor receptor)

EGFR mutation • EGFR T790M

Tagrisso (osimertinib) • Ameile (aumolertinib) • Ivesa (firmonertinib) • Lazcluze (lazertinib) • JIN-A02 • silevertinib (BDTX-1535) • Semena (befotertinib) • Zegfrovy (sunvozertinib) • Rui Bi Da (rezivertinib) • BPI-361175 • BBT-207 • HS-10375 • QLH11811 • TQB3804

over2years

First-in-Human Study of BBT-207 in Advanced Non-Small Cell Lung Cancer Harboring EGFR Mutation After Treatment With EGFR TKI (clinicaltrials.gov)

P1/2, N=92, Not yet recruiting, Bridge Biotherapeutics, Inc.

over 2 years ago

New P1/2 trial • Metastases

EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR C797S

BBT-207